Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
April 10, 2017 3:30 pm ET
Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that Dr. John H. Noseworthy, president and chief
executive officer of Mayo Clinic, has been nominated to stand for
election to the company’s board of directors. The annual election of Dr.
Noseworthy and the other directors will take place in connection with
Merck’s Annual Meeting of Shareholders on May 23, 2017. With the
proposed addition of Dr. Noseworthy, and the planned retirement of C.
Robert Kidder, the Merck board will include 13 members.
“We are pleased to nominate Dr. John Noseworthy to stand for election to
the Merck board and look forward to benefiting from his first-hand
insights about patient care and health care delivery as a leader of one
of the largest non-profit health systems in the United States,” said
Kenneth C. Frazier, chairman and chief executive officer, Merck.
Dr. John H. Noseworthy is president and chief executive officer of Mayo
Clinic, a not-for-profit organization operating in five states that is
dedicated to medical care, research and education. Prior to his current
appointment, he served as chair of Mayo Clinic’s Department of
Neurology, medical director of the Department of Development, and vice
chair of the Mayo Clinic Rochester Executive Board. Dr. Noseworthy is a
professor in the Department of Neurology and served as editor-in-chief
for Neurology, the official journal of the American Academy of
Neurology.
Dr. Noseworthy earned his medical degree from Dalhousie University in
Halifax, Nova Scotia, Canada. He completed his neurology training at
Dalhousie University and the University of Western Ontario, and a
research fellowship at Harvard Medical School. He has received the
Alumnus of the Year award from Dalhousie University, an honorary
doctorate of science degree from the University of Western Ontario, and
an honorary doctorate of laws from Dalhousie University. He also is a
Health Governor of the World Economic Forum.
About Merck
For over a century, Merck has been a global health care leader working
to help the world be well. Merck is known as MSD outside the United
States and Canada. Through our prescription medicines, vaccines,
biologic therapies, and animal health products, we work with customers
and operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
health care through far-reaching policies, programs and partnerships.
For more information, visit www.merck.com
and connect with us on Twitter,
Facebook,
YouTube
and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2016 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Merck
Media:
Tracy Ogden, 215-370-5597
or
Investors:
Teri Loxam, 908-740-1986
